 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ:AERI, an ophthalmic pharmaceutical company, today reported positive topline results for the Companys Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02 netarsudil 0.02 versus ripasudil hydrochloride hydrate ophthalmic solution 0.4 ripasudil 0.4. The results showed that netarsudil 0.02 once daily was superior to ripasudil 0.4 twice daily in lowering intraocular pressure IOP at week 